Related Experiment Videos
Interferon-α2a treatment for refractory Behçet's disease
1Department of Ophthalmology, Mackay Memorial Hospital, Taipei, Taiwan.
Taiwan Journal of Ophthalmology
|October 9, 2018
Summary
Interferon-alpha2a (IFN-α2a) offers a potential treatment for Behçet's disease uveitis when other therapies fail. This case study shows sustained vision improvement and disease control with IFN-α2a.
Area of Science:
- Ophthalmology
- Immunology
- Rheumatology
Background:
- Behçet's disease is a rare multisystem inflammatory disorder.
- Ocular involvement, particularly uveitis, can lead to significant vision loss.
- Standard immunosuppressive therapies like azathioprine, cyclosporine, and prednisolone may be insufficient for sight-threatening uveitis.
Observation:
- A young male patient with Behçet's disease experienced recurrent sight-threatening uveitis despite conventional treatments.
- Initial response to anti-tumor necrosis factor-alpha (TNF-α) therapy (adalimumab) was temporary, with relapse upon discontinuation.
- Reintroduction of anti-TNF-α therapy provided inadequate control.
Findings:
- Interferon-alpha2a (IFN-α2a), combined with low-dose prednisone, effectively controlled severe uveitis.
- Sustained IFN-α2a therapy (3 times/week for 2 years) prevented recurrence and improved visual acuity.
- Despite side effects (flu-like symptoms, fever, depression), discontinuing IFN-α2a led to rapid relapse.
Implications:
- IFN-α2a represents a promising therapeutic option for refractory Behçet's uveitis.
- This case highlights the potential role of IFN-α2a in managing severe ocular manifestations of Behçet's disease.
- Further research is warranted to establish optimal IFN-α2a treatment strategies for Behçet's uveitis, particularly in specific populations like Taiwan.